Repositioning Candidate Details
| Candidate ID: | R0764 |
| Source ID: | DB05303 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | OMS-103HP |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in inflammatory disorders (unspecified), knee replacement, orthopedic surgery, and pain (acute or chronic). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | OMS-103HP is used to inhibit inflammation and pain associated with arthroscopy, provided statistically significant improvement in postoperative pain reduction, joint motion and recovery of function. It is a unique product that is added to standard irrigation solutions and perfused through the joint during arthroscopic surgery. |
| Targets: | Tumor necrosis factor; Interleukin-1 receptor type 1 |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|